What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks. Since retirement is ...

Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billio ...

Experts debate MMR/p53 testing, liquid biopsy, and immunotherapy sequencing in endometrial cancer, refining prognosis and relapse treatment.

Shares of Biogen Inc. rallied 8.53% to $201.18 Friday, on what proved to be an all-around great trading session for the stock ...

The Trump administration launched its new TrumpRx prescription drug listing site late Thursday, part of a push by President Trump to offer lower direct-to-consumer drug prices.

Yesterday was not a good day for the markets. The S&P 500 lost 1.23% on Thursday, and the Dow lost 1.20%. Meanwhile, tech and ...

Pfizer plans to use a higher dose of the drug in phase three trials, and Bourla said it will produce efficacy and ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

One panelist accused the F.D.A. of withholding data on potential harms. The advisers also are reviewing research on vaccines ...

The stock price of BridgeBio plunged 15% Thursday as Pfizer's reported decision to withdraw a Vyndamax patent in the European Union triggered fears of earlier generic entry in the blockbuster ...

The U.S. FDA has accepted and granted Priority Review for Pfizer’s supplemental Biologics License Application (sBLA) for HYMPAVZI.